Breakthrough research on radioactive element could lead to new weapon against cancer

A new weapon against cancer could be just around the corner now that a Cal Poly Pomona professor and her colleagues from Stanford, Cornell and Los Alamos National Laboratory have unlocked some of the secrets of a fickle radioactive element.

Chantal Stieber, an assistant professor of chemistry and biochemistry at Cal Poly Pomona, and her peers researched the properties of actinium, which belongs to the set of elements that includes uranium and plutonium. It has been explored as a potential component of anti-cancer treatments, but its short half-life caused it to break down before it could easily be studied, preventing researchers from developing drugs that specifically target tumors without damaging other parts of the body.

To learn more about how actinium bonds with other atoms to create chemical compounds, the team made use of X-ray absorption spectroscopy, a technique in which the sample being analyzed is bombarded with powerful X-rays, causing its atoms to absorb the rays in a way that reveals information about their atomic structure.

The team found that when actinium was dissolved in a solution, it bonded to neighboring atoms differently than had been previously thought. This knowledge is vital to the production of actinium-based drugs for targeted alpha therapy — a medical treatment in which radioactive isotopes are introduced into the human body to target malignant cells without harming healthy tissue.

Source: California State Polytechnic University Pomona

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Breakthrough study unravels molecular subtypes of breast cancer